STERIS plc $STE Shares Sold by London Co. of Virginia

London Co. of Virginia trimmed its stake in STERIS plc (NYSE:STE) by 4.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 790,071 shares of the medical equipment provider’s stock after selling 38,615 shares during the quarter. London Co. of Virginia’s holdings in STERIS were worth $195,496,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of STE. Steigerwald Gordon & Koch Inc. purchased a new position in STERIS during the third quarter worth approximately $25,000. Cloud Capital Management LLC purchased a new stake in shares of STERIS during the 3rd quarter valued at $29,000. Geneos Wealth Management Inc. increased its holdings in shares of STERIS by 416.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 104 shares during the last quarter. TruNorth Capital Management LLC acquired a new stake in shares of STERIS during the 3rd quarter worth $37,000. Finally, Root Financial Partners LLC purchased a new position in shares of STERIS in the 3rd quarter worth $39,000. Institutional investors and hedge funds own 94.69% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on STE shares. Wall Street Zen upgraded STERIS from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a research note on Friday, January 9th. Six analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $275.20.

Insider Buying and Selling

In related news, Director Cynthia L. Feldmann sold 3,098 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $237.21, for a total transaction of $734,876.58. Following the transaction, the director directly owned 705 shares of the company’s stock, valued at approximately $167,233.05. The trade was a 81.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 1.07% of the company’s stock.

STERIS Stock Up 2.1%

Shares of STERIS stock opened at $219.18 on Tuesday. STERIS plc has a twelve month low of $204.90 and a twelve month high of $269.44. The stock has a market cap of $21.49 billion, a price-to-earnings ratio of 30.57 and a beta of 1.05. The company has a current ratio of 2.48, a quick ratio of 1.75 and a debt-to-equity ratio of 0.26. The company has a fifty day moving average price of $250.22 and a 200 day moving average price of $250.34.

STERIS (NYSE:STE) last released its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $2.53 EPS for the quarter, meeting the consensus estimate of $2.53. STERIS had a return on equity of 14.34% and a net margin of 12.15%.The firm’s quarterly revenue was up 9.2% on a year-over-year basis. During the same period last year, the firm earned $2.32 EPS. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. Equities research analysts forecast that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 19th. Investors of record on Tuesday, February 17th will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Tuesday, February 17th. STERIS’s dividend payout ratio (DPR) is presently 35.15%.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.